Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

NARecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;

Induction Phase Regimen

DRUG

Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;

Consolidation therapy after remission

OTHER

utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Trial Locations (1)

210000

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

Huai'an First People's Hospital

OTHER

collaborator

Yancheng First People's Hospital

OTHER

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06232694 - Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | Biotech Hunter | Biotech Hunter